Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis

Summary

The purpose of this pilot study is to assess the safety and tolerability of multiple doses of MaaT033 in ALS patients and to analyze the gut microbiota composition and evolution before considering a larger randomized controlled efficacy study.

Timeline

Start

2023-06-08

Primary completion

2024-07-22

Completion

2024-07-22

Outcome

Met primary endpoint

release “Phase 1b clinical trial named IASO ( NCT05889572 ) evaluating MaaT033 in ALS has met its primary endpoint” maatpharma.com ↗

release “evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS). In November 2024 , the Company announced that the trial had met its primary endpoint” maatpharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MaaT033	Other / unclassified	—	Oral

Indications